Search research articles
Contact Us
Filters
Showing results (31-40 of 50) with videos related to
Page
of 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors
Kyriakos P Papadopoulos, Josep Tabernero, Ben Markman, et al.
Future Oncology (London, England)
|
August 18, 2023
The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor
William D Tap, Maitreyi G Sharma, Marc Vallee, et al.
International Journal of Molecular Sciences
|
August 29, 2024
Integrative Analysis of Transcriptomic Profiles and Physiological Responses Provide New Insights into Drought Stress Tolerance in Oil Palm (<i>Elaeis guineensis</i> Jacq.)
Fernan Santiago Mejía-Alvarado, Arley Fernando Caicedo-Zambrano, David Botero-Rozo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 7, 2014
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer
Giorgio V Scagliotti, Enriqueta Felip, Benjamin Besse, et al.
Cancer
|
April 26, 2017
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors
Kathleen N Moore, Hossein Borghaei, David M O'Malley, et al.
Future Oncology (London, England)
|
September 4, 2024
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with <i>KIT</i> exon 11 + 17/18 mutations
Suzanne George, Jean-Yves Blay, Ping Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2020
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Filip Janku, Albiruni R Abdul Razak, Ping Chi, et al.
The Lancet. Oncology
|
June 9, 2020
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay, César Serrano, Michael C Heinrich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
Suzanne George, Ping Chi, Michael C Heinrich, et al.
Molecular Cancer Therapeutics
|
August 26, 2021
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
Bryan D Smith, Michael D Kaufman, Scott C Wise, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 50) with videos related to
Sort By:
Page
of 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors
Kyriakos P Papadopoulos, Josep Tabernero, Ben Markman, et al.
Future Oncology (London, England)
|
August 18, 2023
The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor
William D Tap, Maitreyi G Sharma, Marc Vallee, et al.
International Journal of Molecular Sciences
|
August 29, 2024
Integrative Analysis of Transcriptomic Profiles and Physiological Responses Provide New Insights into Drought Stress Tolerance in Oil Palm (<i>Elaeis guineensis</i> Jacq.)
Fernan Santiago Mejía-Alvarado, Arley Fernando Caicedo-Zambrano, David Botero-Rozo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 7, 2014
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer
Giorgio V Scagliotti, Enriqueta Felip, Benjamin Besse, et al.
Cancer
|
April 26, 2017
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors
Kathleen N Moore, Hossein Borghaei, David M O'Malley, et al.
Future Oncology (London, England)
|
September 4, 2024
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with <i>KIT</i> exon 11 + 17/18 mutations
Suzanne George, Jean-Yves Blay, Ping Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2020
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Filip Janku, Albiruni R Abdul Razak, Ping Chi, et al.
The Lancet. Oncology
|
June 9, 2020
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay, César Serrano, Michael C Heinrich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
Suzanne George, Ping Chi, Michael C Heinrich, et al.
Molecular Cancer Therapeutics
|
August 26, 2021
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
Bryan D Smith, Michael D Kaufman, Scott C Wise, et al.
Page
of 5